[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ECSP066792A - Cetoamidas novedosas con p4 cíclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c - Google Patents

Cetoamidas novedosas con p4 cíclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c

Info

Publication number
ECSP066792A
ECSP066792A EC2006006792A ECSP066792A ECSP066792A EC SP066792 A ECSP066792 A EC SP066792A EC 2006006792 A EC2006006792 A EC 2006006792A EC SP066792 A ECSP066792 A EC SP066792A EC SP066792 A ECSP066792 A EC SP066792A
Authority
EC
Ecuador
Prior art keywords
cetoamids
hepatitis
virus
inhibitors
newly
Prior art date
Application number
EC2006006792A
Other languages
English (en)
Inventor
Viyyoor M Girijavallabhn
Frank Bennett
Stephane L Bogen
F George Njoroge
Ashok Arasappan
Kevin X Chen
Srikanth Venkatraman
Latha G Nair
Bancha Vibulbhan
Mousumi Sannigrahi
Weiying Yang
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34919371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066792(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP066792A publication Critical patent/ECSP066792A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención describe novedosos compuestos los cuales tienen actividad inhibitoria de la proteasa de VHC así como también métodos para preparar dichos compuestos. En otra realización, la invención describe composiciones farmacéuticas que comprenden ese tipo de compuestos así como también métodos para su utilización para tratar trastornos asociados con la proteasa de VHC.
EC2006006792A 2004-02-27 2006-08-25 Cetoamidas novedosas con p4 cíclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c ECSP066792A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54850604P 2004-02-27 2004-02-27

Publications (1)

Publication Number Publication Date
ECSP066792A true ECSP066792A (es) 2006-11-16

Family

ID=34919371

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006792A ECSP066792A (es) 2004-02-27 2006-08-25 Cetoamidas novedosas con p4 cíclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c

Country Status (18)

Country Link
US (2) US7173057B2 (es)
EP (1) EP1730142B1 (es)
JP (1) JP4874227B2 (es)
KR (1) KR20070026394A (es)
CN (1) CN1946718A (es)
AR (1) AR048023A1 (es)
AT (1) ATE514691T1 (es)
AU (1) AU2005219824B2 (es)
BR (1) BRPI0508217A (es)
CA (1) CA2557304C (es)
EC (1) ECSP066792A (es)
IL (1) IL177628A0 (es)
NO (1) NO20064355L (es)
PE (1) PE20050999A1 (es)
RU (1) RU2006134000A (es)
TW (1) TW200529822A (es)
WO (1) WO2005085242A1 (es)
ZA (1) ZA200607048B (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100509388B1 (ko) 1996-10-18 2005-08-23 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 간염 ｃ 바이러스 ｎｓ３ 프로테아제의 저해제
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US8602716B2 (en) * 2003-11-10 2013-12-10 Brooks Automation, Inc. Semiconductor manufacturing process modules
US8696298B2 (en) * 2003-11-10 2014-04-15 Brooks Automation, Inc. Semiconductor manufacturing process modules
US10086511B2 (en) 2003-11-10 2018-10-02 Brooks Automation, Inc. Semiconductor manufacturing systems
KR20060127162A (ko) * 2004-02-27 2006-12-11 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ3 세린 프로테아제의 억제제로서의화합물
US7635694B2 (en) * 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
US20060276404A1 (en) * 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
US20060275366A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
US20060276407A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
PE20070011A1 (es) * 2005-06-02 2007-03-08 Schering Corp Formulaciones farmaceuticas de compuestos inhibidores de proteasa del vhc o catepsina
US20070021351A1 (en) * 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
US20060276406A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
AU2006252623A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation useful for treating disorders associated with hepatitis C virus
WO2006130626A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period
AU2006252519B2 (en) 2005-06-02 2012-08-30 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
JP5249028B2 (ja) 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
NZ568135A (en) 2005-10-11 2011-06-30 Array Biopharma Inc Macrocyclic compounds and methods for inhibiting hepatitis C viral replication
EP2392590A3 (en) 2005-11-11 2012-03-14 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7705138B2 (en) * 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
KR20080104366A (ko) * 2006-04-11 2008-12-02 노파르티스 아게 Ｈｃｖ 억제제
UA100666C2 (uk) 2006-04-11 2013-01-25 Новартіс Аг Інгібітори нсv/віл та їх застосування
US20080045530A1 (en) * 2006-04-11 2008-02-21 Trixi Brandl Organic Compounds and Their Uses
KR20090024834A (ko) 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
CN101506167A (zh) 2006-08-17 2009-08-12 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
EP2099430A2 (en) 2006-12-07 2009-09-16 Schering Corporation Ph sensitive matrix formulation
MX2009010205A (es) * 2007-03-23 2009-10-19 Schering Corp Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c.
CA2681598A1 (en) * 2007-03-23 2008-10-02 Schering Corporation Hydrazido-peptides as inhibitors of hcv ns3-protease
JP2010528987A (ja) * 2007-05-03 2010-08-26 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
AR066528A1 (es) 2007-05-10 2009-08-26 Array Biopharma Inc Peptidos inhibidores de la replicacion del virus de la hepatitis c
CA2693997C (en) 2007-08-03 2013-01-15 Pierre L. Beaulieu Viral polymerase inhibitors
MX2010003916A (es) * 2007-10-10 2010-05-05 Novartis Ag Espiro-pirrolidinas y su uso contra infeccion por el virus de hepatitis c (hcv) y por el virus de inmunodeficiencia humana (vih).
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
TW200936131A (en) 2008-02-04 2009-09-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
KR20110005869A (ko) 2008-04-15 2011-01-19 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제
RU2011127080A (ru) 2009-01-07 2013-02-20 Сайнексис, Инк. Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
EP2403860B1 (en) 2009-03-04 2015-11-04 IDENIX Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8980920B2 (en) 2009-05-29 2015-03-17 Merck Sharp & Dohme Corp. Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C
JP2013501068A (ja) 2009-08-05 2013-01-10 アイディニックス ファーマシューティカルズ インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
JP2013512246A (ja) 2009-11-25 2013-04-11 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
SG181797A1 (en) 2009-12-18 2012-07-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
CA2792121A1 (en) 2010-03-09 2011-09-15 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
AU2011286276A1 (en) 2010-07-26 2013-01-24 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
EP2621279B1 (en) 2010-09-29 2018-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
JP5565320B2 (ja) * 2011-01-06 2014-08-06 富士通株式会社 情報処理装置及び情報処理プログラム
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
KR20130138840A (ko) 2011-04-13 2013-12-19 머크 샤프 앤드 돔 코포레이션 2''-치환된 뉴클레오시드 유도체 및 바이러스성 질환의 치료를 위한 그의 사용 방법
WO2012158861A2 (en) 2011-05-18 2012-11-22 Enanta Pharmaceuticals, Inc. Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme HETEROCYCLIC COMPOUNDS CONTAINING SILYL AND METHODS OF USING THE SAME FOR TREATING VIRAL DISEASES
US20160229866A1 (en) 2013-09-20 2016-08-11 Idenix Pharmaceuticals Inc. Hepatitis c virus inhibitors
WO2015065817A1 (en) 2013-10-30 2015-05-07 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
EP3114122A1 (en) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid forms of a flaviviridae virus inhibitor compound and salts thereof
CN104292130B (zh) * 2014-10-13 2016-04-27 苏州永健生物医药有限公司 一种波普瑞韦中间体2-羟基-3-氨基-4-环丁基丁酰胺盐酸盐的合成方法
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2023011443A1 (zh) * 2021-08-02 2023-02-09 北京华益健康药物研究中心 用于治疗或预防冠状病毒感染的3cl蛋白酶小分子抑制剂及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4506666A (en) * 1982-12-03 1985-03-26 Kircaldie, Randall And Mcnab Method and apparatus for rectifying obstructive apnea
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
KR100939155B1 (ko) * 2000-07-21 2010-01-28 쉐링 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제 억제제로서의신규한 펩티드
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
CA2462163A1 (en) * 2001-10-24 2003-05-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
JP4301953B2 (ja) * 2002-01-23 2009-07-22 シェーリング コーポレイション Ｃ型肝炎ウイルス感染の処置における使用のためのｎｓ３−セリンプロテアーゼ阻害剤としてのプロリン化合物
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
JP2005173784A (ja) * 2003-12-09 2005-06-30 Nec Corp 映像情報配信システム及び方法と装置並びにプログラム
US7245891B2 (en) * 2003-10-21 2007-07-17 Kyocera Wireless Corp. Wireless mobile communication device having a speaker vibration alert and method of using same
DE602005015834D1 (de) * 2004-02-27 2009-09-17 Schering Corp 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
US7635694B2 (en) * 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease

Also Published As

Publication number Publication date
IL177628A0 (en) 2006-12-31
EP1730142B1 (en) 2011-06-29
KR20070026394A (ko) 2007-03-08
ATE514691T1 (de) 2011-07-15
WO2005085242A1 (en) 2005-09-15
EP1730142A1 (en) 2006-12-13
AR048023A1 (es) 2006-03-22
JP2007525518A (ja) 2007-09-06
CA2557304C (en) 2013-08-06
ZA200607048B (en) 2008-06-25
CA2557304A1 (en) 2005-09-15
JP4874227B2 (ja) 2012-02-15
US7173057B2 (en) 2007-02-06
PE20050999A1 (es) 2005-12-01
RU2006134000A (ru) 2008-04-10
AU2005219824B2 (en) 2007-11-29
US7619094B2 (en) 2009-11-17
TW200529822A (en) 2005-09-16
US20050222047A1 (en) 2005-10-06
US20070093430A1 (en) 2007-04-26
NO20064355L (no) 2006-11-24
BRPI0508217A (pt) 2007-07-17
AU2005219824A1 (en) 2005-09-15
CN1946718A (zh) 2007-04-11

Similar Documents

Publication Publication Date Title
ECSP066792A (es) Cetoamidas novedosas con p4 cíclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c
ECSP066795A (es) Compuestos novedosos como inhibidores de ns3 serina proteasa del virus de hepatitis c
ECSP066794A (es) Nuevos compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c
ECSP066626A (es) Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c
ECSP099685A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
ECSP066791A (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
ECSP034439A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
CL2012001230A1 (es) Compuestos derivados de biciclos, inhibidores de la proteina ns5a; composicion farmaceutica que los comprende; uso en el tratamiento de la hepatitis c.
CR20150058A (es) Inhibidores de la proteasa ns3 del hcv
ECSP034438A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
CO6390076A2 (es) Inhibidores de hcv ns5a
CO6390077A2 (es) Inhibidores de hacv ns5a
CL2012001176A1 (es) Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv.
MX2009010207A (es) Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
EA201171174A1 (ru) Ингибиторы репликации вируса гепатита c
GT200600317A (es) Inhibidores de la proteasa ns3 del vhc
AR029851A1 (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
ECSP088518A (es) Nucleósidos antivirales
CO6561788A2 (es) Inhibidores del virus de la hepatitis c
CO6400192A2 (es) Inhibidores del virus de la hepatitis c
CO6361922A2 (es) Inhibidores del virus de la hepatitis c
EA200901241A1 (ru) Соединения для лечения гепатита с
MX2009010205A (es) Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c.
MX2010004704A (es) Inhibidores macrociclicos de la ns3 serina proteasa del virus de la hepatitis c.